Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 2/2011

01-02-2011 | Urologic Oncology

A Contemporary Population-Based Assessment of the Rate of Lymph Node Dissection for Penile Carcinoma

Authors: Rodolphe Thuret, MD, Maxine Sun, BSc, Giovanni Lughezzani, MD, Lars Budaus, MD, Daniel Liberman, MD, Firas Abdollah, MD, Monica Morgan, MD, Rupinder Johal, MD, Claudio Jeldres, MD, Mathieu Latour, MD, Shahrokh F. Shariat, MD, François Iborra, MD, Jacques Guiter, MD, Jean-Jacques Patard, MD, Paul Perrotte, MD, Pierre I. Karakiewicz, MD, FRCSC

Published in: Annals of Surgical Oncology | Issue 2/2011

Login to get access

Abstract

Background

The adherence rate to National Cancer Institute (NCI) recommendations regarding inguinal lymph nodes dissection (ILND) in high grade T1 (G3T1) and T2-4 squamous cell carcinoma of the penis (SCCP) is not known. We assessed ILND rates in a North American cohort.

Materials and Methods

The 17 registries of the Surveillance, Epidemiology, and End Results (SEER) database included 868 patients with SCCP, diagnosed between 1988 and 2006. Analyses consisted of univariable and multivariable logistic regression models.

Results

Overall, 27.6% of patients underwent an ILND. ILND rates were directly proportional with T stage: 19.0%, 30.5%, 30.6%, and 32.6% for, respectively, G3T1, T2, T3, and T4 SCCP (chi-square trend, P = 0.01). ILND rates also increased over time and were 19.3, 27.3, 30.7, and 30.8% for respectively, 1988–1995, 1996–2000, 2001–2003, and 2004–2006 periods (chi-square trend, P = 0.03). Finally, ILND rates decreased with patient age and were 42.6, 33.2, 24.7, and 7.3% for, respectively, patients aged ≤57, 58–68, 69–78 and ≥79 years of age (chi-square trend, P < 0.001). All 3 variables (T-stage, year of primary tumor excision and patient age) achieved independent predictor status in multivariable analyses.

Conclusions

The overall rate of ILND is low. Nonetheless, there is an upward trend over time. Our data indicate that the adherence to the NCI ILND guidelines is suboptimal. In consequence, ILNDs should be more strongly encouraged.
Literature
1.
2.
Ficarra V, Zattoni F, Cunico CSC, Galetti TP, Luciani L, Fandella A, et al. Lymphatic and vascular embolizations are independent predictive variables of inguinal lymph node involvement in patients with squamous cell carcinoma of the penis. Cancer. 2005;103:2507–16.
3.
Hegarty PK, Kayes O, Freeman A, Christopher N, Ralph DJ, Minhas S. A prospective study of 100 cases of penile cancer managed according to European Association of Urology guidelines. BJU Int. 2006;98:526–31.CrossRefPubMed
4.
Ornellas AA, Kinchin EW, Nobrega BL, Wisnescky A, Koifman N, Quirino R. Surgical treatment of invasive squamous carcinoma of the penis: Brazilian National Cancer Institute long-term experience. J Surg Oncol. 2008;97:487–95.CrossRefPubMed
5.
6.
Ornellas AA, Seixas AL, Marota A, Wisnescky A, Campos F, de Moraes JR. Surgical treatment of invasive squamous carcinoma of the penis: retrospective analysis of 350 cases. J Urol. 1994;151:1244–9.PubMed
7.
Horenblas S, Van Tinteren H, Delemarre JF, Moonen LM, Lustig V, van Waardenburg EW. Squamous cell carcinoma of the penis. III. Treatment of regional lymph nodes. J Urol. 1993;149:492–7.PubMed
8.
Lopes A, Hidalgo GS, Kowalski LP, Torloni H, Rossi BM, Fonseca FP. Prognostic factors in carcinoma of the penis: multivariate analysis of 145 patients treated with amputation and lymphadenectomy. J Urol. 1996;156:1637–42.CrossRefPubMed
9.
McDougal WS, Kirchner Jr. FK, Edwards RH, Killion LT. Treatment of carcinoma of the penis: the case for primary lymphadenectomy. J Urol. 1986;136:38–41.PubMed
10.
Kroon BK, Horenblas S, Long AP, Tanis PJ, Gallee MP, Nieweg OE. Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol. 2005;173:816–19.CrossRefPubMed
11.
12.
Sobin LH, Wittekind CH. TNM Classification of Malignant Tumours. 6th ed. 2002.
13.
14.
15.
Du XL, Fang S, Coker AL, Sanderson M, Aragaki C, Cormier JN, et al. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma. Cancer. 2005;106:1276–85.CrossRef
16.
Robert SA, Strombom I, Trentham-Dietz A, Hampton JM, McElroy JA, Newcomb PA, et al. Socioeconomic risk factors for breast cancer—distinguishing individual- community-level effects. Epidemiology. 2004;14:442–50.CrossRef
17.
Persson B, Sjodin JG, Holmberg L, Windahl T, Steering Committee of the National Penile Cancer Register in Sweden. The national penile cancer register in Sweden 2000-2003. Scand J Urol Nephrol. 2007;41:278–82.CrossRefPubMed
18.
Leijte JAP, Kirrander P, Antonini N, Windahl, T, Horenblas S. Recurrence patterns of squamous cell carcinoma of the penis: Recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol. 2008;54:161–8.CrossRefPubMed
19.
Protzel C, Alcaraz A, Horenblas S, Pizzocaro G, Zlotta A, Hakenberg OW. Lymphadenectomy in the surgical management of penile cancer. Eur Urol. 2009;55:1075–88.CrossRefPubMed
Metadata
Title
A Contemporary Population-Based Assessment of the Rate of Lymph Node Dissection for Penile Carcinoma
Authors
Rodolphe Thuret, MD
Maxine Sun, BSc
Giovanni Lughezzani, MD
Lars Budaus, MD
Daniel Liberman, MD
Firas Abdollah, MD
Monica Morgan, MD
Rupinder Johal, MD
Claudio Jeldres, MD
Mathieu Latour, MD
Shahrokh F. Shariat, MD
François Iborra, MD
Jacques Guiter, MD
Jean-Jacques Patard, MD
Paul Perrotte, MD
Pierre I. Karakiewicz, MD, FRCSC
Publication date
01-02-2011
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 2/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1315-6

Other articles of this Issue 2/2011

Annals of Surgical Oncology 2/2011 Go to the issue

Endocrine Tumors

Robotic-Assisted Resection of Adrenal Aldosteronoma

Bone and Soft Tissue Sarcomas

Radiotherapy for Soft Tissue Sarcomas after Isolated Limb Perfusion and Surgical Resection: Essential for Local Control in All Patients?

Hepatobiliary Tumors

Sinusoidal Obstruction Syndrome Impairs Long-Term Outcome of Colorectal Liver Metastases Treated with Resection after Neoadjuvant Chemotherapy

Translational Research and Biomarkers

Reduced Expression of Reelin (RELN) Gene Is Associated With High Recurrence Rate of Hepatocellular Carcinoma

Thoracic Oncology

Comparison of p53 and Epidermal Growth Factor Receptor Gene Status Between Primary Tumors and Lymph Node Metastases in Non-Small Cell Lung Cancers

Hepatobiliary Tumors

Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Prospective Comparative Study